SignalHF vs Tempus ECG-AF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

SignalHF

by Implicity

Tempus ECG-AF

by Tempus AI, Inc.

AI Verdict

SignalHF and Tempus ECG-AF are both FDA-cleared AI tools in cardiology, but they serve distinct clinical purposes. SignalHF focuses on predicting heart failure hospitalizations in patients with cardiac implantable electronic devices, while Tempus ECG-AF identifies the risk of new-onset atrial fibrillation in older patients using ECG data. Therefore, they are not direct competitors but rather complementary tools addressing different aspects of cardiac care.

Choose SignalHF if…

Choose SignalHF if your primary goal is to proactively prevent heart failure hospitalizations in patients already equipped with cardiac implantable electronic devices (CIEDs). This tool is ideal for care teams managing a population with pacemakers, ICDs, or CRTs, seeking to leverage AI-driven insights from device data for early intervention and personalized care plans to reduce re-admissions within 30 days.

View SignalHF →

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if you need to identify older patients (65+) without a pre-existing atrial fibrillation diagnosis or cardiac implants who are at an increased risk of developing new-onset AF within the next 12 months. This solution is best suited for screening efforts using standard 12-lead ECG recordings to enable earlier detection and follow-up for at-risk individuals.

View Tempus ECG-AF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	SignalHF	Tempus ECG-AF
Pricing	Contact for pricing	Contact vendor
Deployment	SaaS	Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.
BAA Available	Yes AI-estimated	Yes AI-estimated
FDA Status	Cleared AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	SignalHF	Tempus ECG-AF
Name	SignalHF	Tempus ECG-AF
Company	Implicity	Tempus AI, Inc.
Description	FDA-cleared AI algorithm that predicts heart failure hospitalizations within 30 days by analyzing data from various cardiac implantable electronic devices, enabling early intervention and personalized care.	FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up.
Target Condition	Heart Failure Hospitalizations	Atrial Fibrillation/Flutter (AF)
Data Source	Various cardiac implantable electronic devices (CIEDs)	12-lead ECG recordings
Prediction Horizon	Within 30 days	Within the next 12 months
Target Patient Population	Not specified	Patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery

Videos

Demos, reviews, and walkthroughs featuring SignalHF and Tempus ECG-AF.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What specific cardiovascular conditions do these AI tools address?

SignalHF is an FDA-cleared AI algorithm designed to predict heart failure hospitalizations within 30 days. Tempus ECG-AF is an FDA-cleared AI-based algorithm that identifies patients at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months.

What type of patient data is analyzed by each tool?

SignalHF analyzes data from various cardiac implantable electronic devices (CIEDs), including pacemakers, ICDs, and CRTs, considering physiological data, demographics, lead measurements, episodes, and therapies. Tempus ECG-AF analyzes 12-lead ECG recordings.

For which patient populations are these tools intended?

SignalHF is intended for qualified healthcare professionals managing patients over 18 years old who are receiving physiological monitoring for heart failure surveillance and are implanted with a compatible CIED. Tempus ECG-AF is for patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.

How do the tools differ in terms of their prediction horizon and output?

SignalHF predicts heart failure hospitalizations within 30 days and generates automatic alerts for care teams based on risk scores. Tempus ECG-AF identifies patients at increased risk of developing AF within the next 12 months, supporting earlier identification and follow-up.

What are the compatibility requirements for each tool's data input?

SignalHF offers manufacturer-agnostic compatibility with various CIEDs from brands like Biotronik, Boston Scientific, and Medtronic. Tempus ECG-AF is compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems.

How are the results from each tool intended to be integrated into clinical practice?

SignalHF generates alerts to enable early intervention and personalized care plans, providing actionable insights for care teams. Tempus ECG-AF's results should be interpreted in conjunction with other diagnostic information and clinical history to support earlier identification and follow-up for AF.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring SignalHF or Tempus ECG-AF

Backers

Who funded each tool's parent company.

SignalHF

Serena